ArticleFrontiers in pharmacology2022

Exploring a four-gene risk model based on doxorubicin resistance-associated lncRNAs in hepatocellular carcinoma.

Zunyi Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.